Signifikant bedre PFS ved 1. linjebehandling af avanceret renalcelle karcinom

BestPractice | Nov 2018 | ESMO 2018 |

I denne MEDtalk fremlægger Robert Motzer,Memorial Sloan Kettering Cancer Center, New York City, resultaterne fra JAVELIN Renal 101, der viser, at kombinationsbehandlingen med avelumab og axitinib signifikant forbedrer PFS 1. linjebehandling af avanceret renalcelle karcinom.

 

<script src=”https://fast.wistia.com/embed/medias/ovj13kpr5k.jsonp” async></script><script src=”https://fast.wistia.com/assets/external/E-v1.js” async></script><div class=”wistia_responsive_padding” style=”padding:56.25% 0 0 0;position:relative;”><div class=”wistia_responsive_wrapper” style=”height:100%;left:0;position:absolute;top:0;width:100%;”><div class=”wistia_embed wistia_async_ovj13kpr5k seo=false videoFoam=true” style=”height:100%;position:relative;width:100%”><div class=”wistia_swatch” style=”height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;”><img src=”https://fast.wistia.com/embed/medias/ovj13kpr5k/swatch” style=”filter:blur(5px);height:100%;object-fit:contain;width:100%;” alt=”” onload=”this.parentNode.style.opacity=1;” /></div></div></div></div>